Inozyme Pharma, a preclinical biotech developing protein therapies for rare calcification diseases, raised $112 million by offering 7 million shares at $16, in line with the upwardly revised terms. The company offered 0.5 million more shares than anticipated. It originally filed to offer 5 million shares at a range of $14 to $16, before increasing its proposed deal size on Thursday morning. At pricing, the company commands a fully diluted market cap of $386 million.
Inozyme Pharma plans to list on the Nasdaq under the symbol INZY. BofA Securities, Cowen, and Piper Sandler acted as lead managers on the deal.
